- $176.73m
- $344.45m
- 35
- 67
- 76
- 61
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | n/a | ||
| Price to Tang. Book | n/a | ||
| Price to Free Cashflow | 2.38 | ||
| Price to Sales | n/a | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -49.37% | ||
| Return on Equity | -576.33% | ||
| Operating Margin | n/a | ||
Financial Summary
| Year End 31st Dec | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | n/a | n/a | n/a | n/a | n/a | 16.67 | 6.5 | -100% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Omeros Corporation is a biopharmaceutical company. The Company is focused on discovering, developing and commercializing small-molecule and protein therapeutics for large-market and orphan indications targeting immunologic disorders, including complement-mediated diseases, cancers, and addictive and compulsive disorders. Its lead MASP-2 inhibitor, narsoplimab, targets the lectin pathway of complement and is the subject of a biologics license application pending before FDA for the treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathy. Its long-acting MASP-2 inhibitor, OMS1029, is in a phase I multi-ascending-dose clinical trial. OMS906, its inhibitor of MASP-3, the key activator of the alternative pathway of complement, is advancing in clinical programs for paroxysmal nocturnal hemoglobinuria and complement 3 glomerulopathy. The Company’s lead phosphodiesterase 7 inhibitor OMS527 is in clinical development for the treatment of cocaine use disorders.
Directors
- Gregory Demopulos CHM (62)
- Michael Jacobsen CAO (62)
- George Gaitanaris CSO (64)
- Peter Cancelmo VPR (42)
- Peter Williams VPR (53)
- Christopher Bral VPR (55)
- Nadia Dac VPR (51)
- Bruce Meiklejohn VPR (61)
- Catherine Melfi VPR (61)
- Tina Quinton VPR (58)
- J. Steven Whitaker VPR (65)
- Timothy Duffy VBD (60)
- Thomas Cable LED (81)
- Peter Demopulos DRC (67)
- Thomas Bumol IND (67)
- Arnold Hanish IND (73)
- Leroy Hood IND (82)
- Rajiv Shah IND (48)
- Kurt Zumwalt IND (52)
- Last Annual
- December 31st, 2023
- Last Interim
- December 31st, 2023
- Incorporated
- June 16th, 1994
- Public Since
- October 8th, 2009
- No. of Shareholders
- 84
- No. of Employees
- 198
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
NASDAQ Global Market- Shares in Issue
- 57,942,695
- Address
- 201 Elliott Avenue West, SEATTLE, 98119
- Web
- https://www.omeros.com/
- Phone
- +1 2066765000
- Auditors
- Ernst & Young LLP
Upcoming Events for OMER
Omeros Corp Annual Shareholders Meeting
Q2 2024 Omeros Corp Earnings Release
Similar to OMER
89bio
NASDAQ Global Market
Abivax SA
NASDAQ Global Market
AC Immune SA
NASDAQ Global Market
Acrivon Therapeutics
NASDAQ Global Market
Adagene
NASDAQ Global Market
FAQ
What is the Omeros share price?
As of Today at 19:16 UTC, shares in Omeros are trading at $3.05. This share price information is delayed by 15 minutes.
How has the Omeros share price performed this year?
Shares in Omeros last closed at $3.05 and the price had moved by -41.46% over the past 365 days. In terms of relative price strength the Omeros share price has underperformed the S&P500 Index by -51.28% over the past year.
What are the analyst and broker recommendations for Omeros?
The overall consensus recommendation for Omeros is Buy. You can view the full broker recommendation list by unlocking its StockReport.
What is the Omeros dividend yield?
Omeros does not currently pay a dividend.
Does Omeros pay a dividend?
Omeros does not currently pay a dividend.
When does Omeros next pay dividends?
Omeros does not currently pay a dividend.
How do I buy Omeros shares?
To buy shares in Omeros you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Omeros?
As of the previous close price of $3.05, shares in Omeros had a market capitalisation of $176.73m.
Where are Omeros shares listed?
Here are the trading details for Omeros:
- Country of listing: United States
- Exchange: NMQ
- Ticker Symbol: OMER
What kind of share is Omeros?
Based on an overall assessment of its quality, value and momentum Omeros is currently classified as a Turnaround. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Omeros share price forecast for 2024?
The analyst consensus target price for shares in Omeros is $43.00. That is 1309.84% above the last closing price of $3.05.
Analysts covering Omeros currently have a consensus Earnings Per Share (EPS) forecast of -$2.23 for the next financial year.
What is the trend in the Omeros share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Omeros. Over the past six months, its share price has outperformed the S&P500 Index by +110.52%.
As of the last closing price of $3.05, shares in Omeros were trading -7.27% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Omeros PE Ratio?
The Omeros PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $3.05.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Omeros?
Omeros' management team is headed by:
- Gregory Demopulos - CHM
- Michael Jacobsen - CAO
- George Gaitanaris - CSO
- Peter Cancelmo - VPR
- Peter Williams - VPR
- Christopher Bral - VPR
- Nadia Dac - VPR
- Bruce Meiklejohn - VPR
- Catherine Melfi - VPR
- Tina Quinton - VPR
- J. Steven Whitaker - VPR
- Timothy Duffy - VBD
- Thomas Cable - LED
- Peter Demopulos - DRC
- Thomas Bumol - IND
- Arnold Hanish - IND
- Leroy Hood - IND
- Rajiv Shah - IND
- Kurt Zumwalt - IND